key: cord-0915365-r26p5grg authors: Scarci, Marco; Raveglia, Federico; Bortolotti, Luigi; Benvenuti, Mauro; Merlo, Luca; Petrella, Lea; Cardillo, Giuseppe; Rocco, Gaetano title: COVID-19 after lung resection in Northern Italy date: 2021-05-11 journal: Semin Thorac Cardiovasc Surg DOI: 10.1053/j.semtcvs.2021.03.038 sha: 6003cc9141cd60839584691c503db3dd69d5f8d4 doc_id: 915365 cord_uid: r26p5grg We reviewed surgical cases from 4 Thoracic Surgery departments in the Lombardia region of Italy, the area mostly affected by Coronavirus pandemic in Europe, with the aim to describe the impact of COVID-19 on the treatment of thoracic surgical patients. Clinical, radiological and laboratory data from patients who underwent lung resection from December 2019 to March 2020 were retrospectively collected until June 2020. Univariable Cox regression models were estimated to evaluate potential prognostic factors for developing COVID-19 and to investigate postoperative mortality among patients who developed symptomatic COVID-19 infection. We examined data from 107 patients. (74 lobectomies, 32 wedge/segmentectomies and 1 pneumonectomy). Twelve patients developed COVID-19 (Group 1), whereas 95 patients were not infected (Group 2). In Group 1, six patients (50%) died from complications related to infection; in Group 2, one patient (1%) died because of non-COVID-19-related causes. Median days from surgery to first symptoms, CT confirmation, clinical confirmation and PCR positivity was 48.1, 54.3, 55.1 and 55.2 respectively. At univariable analysis, DLCO/VA% (p=0.008), duration of the surgery (p=0.009), smoking history (pack/year) (p<0.001), BMI (p<0.001) and number of segments resected (p=0.010) were associated with COVID-19 onset. Moreover, CCI (p<0.001), DLCO/VA% (p=0.002), cigarette pack/year (p<0.001), BMI (p<0.001) and COVID-19 (p<0.001) were associated with death. Patients who undergo lung resection and then develop symptomatic COVID-19 infection are at higher risk of developing severe respiratory complications and postoperative death. Insidious symptoms’ onset may lead to a delay in diagnosis. We suggest two mitigating strategies: 1) Improve symptoms surveillance and isolation during recovery period, 2) Be aware of a potential greater risk of developing symptomatic COVID-19 and death correlated with elevated CCI, BMI, smoking history, DLCO/VA%, number of resected segments and duration of surgery. The first cases of Coronavirus disease 2019 were registered in Wuhan, capital city of the Hubei province, China, in December 2019 (1) . Since then the infection has spread globally and was declared a Public Health Emergency of International Concern on 30 January 2020 by World Health Organization (2) . It is with the first case of secondary transmission which occurred in Codogno, Municipality of Lombardy in the province of Lodi, on February 18, 2020 that the epidemic spread throughout Italy. During the initial period, as well as the peak of the pandemic, the North of the Country, and, in particular the Lombardy region, has been the hardest affected area with 86,384 infected and 15, 784 deaths (data updated on May 21 2020) (3) . In particular, the most affected provinces were Brescia, Bergamo, Milano and Monza Brianza (with 14,345, 12,733, 22,534 and 5,412 cases) (3), whereas overall positive and fatal cases in Italy were 228,658 and 32,616, on the 21 th May 2020 (4) . This data also made the Lombardy region the most distressed area in Europe for highest number of deaths per 100,000 inhabitants on May 15 (5) (6) . In comparison with the general population, patients with cancer in the active phase of the disease have a higher risk of death in the weeks after infection and poorer outcomes than non-cancer patients, as shown in some preliminary studies (7) . Therefore, many thoracic oncology patients, considering their multiple co-morbidities (advanced age, smoking history, emphysema, heart disease), are classified in the "high risk" group. Some of the most important institutions such as the Royal College of Surgeons, The Royal College of Physicians and Surgeons of Canada and the American College of Surgeons, quickly provided expert level surgical recommendations for patients with thoracic malignancies (8) (9) ; however, there is still a lack of studies investigating outcomes and risk factors among patients who underwent thoracic surgery and developed COVID-19. di 22 We reviewed data of patients who underwent lung resection in some of the most affected areas in Lombardy, with the aim to determine which variables are clinical or surgical prognostic factors for developing COVID-19 and for mortality, during postoperative recovery period of 90 days, among patients who developed symptomatic COVID-19 . We retrospectively reviewed and prospectively collected clinical data of all patients who underwent We have also investigated how many days elapsed since the onset of COVID-19 signs and definitive diagnosis by reviewing medical records and by obtaining patients or relatives' statements, in order to determine a timeline in disease management. Our dataset consisted of 30 clinical variables from 107 patients who underwent lung resection. Symptoms at onset included dyspnea (7), chest tightness (4), fatigue (6), dry cough (6) (Table 2 ). Syndrome Coronavirus 2 (SARS-CoV-2) infection during perioperative period (11) (12) (13) , and even fewer studies specifically focus on patients who have underwent thoracic surgery. In that arena a very interesting article has been published by Peng and coworkers (14) from China. They reported the postoperative clinical events involving a series of 11 patients without controlcohort. Of 11 patients, they reported 3 fatal cases after pulmonary or esophageal resection and percentages of severe and critical respiratory pattern of 27.3% and 36.4% respectively, versus 6.1% and 13.8% among overall COVID-19 population in China (15) (16) . Their results seem to correlate COVID-19 and outcomes in thoracic surgery patients. Cai and Coworkers, in their series of 7 cases after thoracic surgery, also concluded that lung resection surgery might be a risk factor for death in patients with COVID-19 in the perioperative period (17) . di 22 Our data shows a dramatic pattern as well, since 16% and 50% of COVID-19 patients developed severe and critical respiratory pattern respectively and we registered 50% fatal cases among symptomatic COVID-19 patients. Secondly, their results highlighted a substantial delay from symptom onset to diagnosis, probably due to a confusing overlap between COVID-19 and thoracic surgery postoperative signs and symptoms. We instead observed a smaller delay (about 7 days) that could be explained because all but 1 patient developed symptoms during recovery when postoperative symptoms should have disappeared or decreased. Indeed, most of patients were readmitted to hospital as soon as symptoms occurred. Their detection was probably facilitated by careful phone follow-up but also by the state of national alert promoted by the media. That suggests the need for a tighter and more rigorous early follow-up during the pandemic period, supported by adequate information on signs and symptoms that patients or relatives must be able to check daily. Our data also showed that smoking history, BMI, number of resected segments, DLCO/VA%, and duration of surgery are potential prognostic factors for onset of COVID-19. As concerns smoking history, we already know that smoking impairs lung immune functions and damages upper airways, increasing risks of contracting a severity of infectious diseases. Therefore, it is not surprising that smoking may be an independent risk for severe COVID-19 progression, including mortality (18) . BMI prognostic value is consistent with recent papers showing that adiposity is strongly linked to COVID-19 (19) . In particular it has been showed that obesity may be a stronger risk factor for susceptibility to SARS-CoV-2 infection and severity of consequent disease, including death. Indeed, excess fat can impair lung and metabolic function, stresses inflammatory pathways and cardiorenal systems, and promotes thrombotic responses. Although our is a small case series, we suggest that, 1) the development of clinically apparent COVID-19 during 90 days postoperative period is a dramatic event, 2) surgeons should be aware of a possible greater risk of disease onset and critical pattern development positively associated with di 22 smoking history, BMI, number of resected segments and negatively with DLCO/VA% and duration of surgery. A very interesting point to address is that the most of patients who got clinically apparent disease presented with symptoms after almost one month from surgery. Even considering an incubation period of 2 weeks (22), we are unable to demonstrate whether the infection occurred during the hospital stay or at home, but what matters is that also the period outside the strict perioperative time seems to be dangerous. Therefore, we suggest a rigorous post-discharge follow-up should be established, covering a recovery phase of almost 3 months, to early identify any possible signs and symptoms, as long as the pandemic lasts. Regulated Outpatient Clinics, phone interview or survey administered by digital application should be encouraged. Moreover, patients should also observe equally rigorous isolation standards, with particular attention to cases who present prognostic factors for COVID-19 development. Taipe and Coworkers, in their case report, also stressed this point suggesting that early diagnosis and use of antibiotics at doses of sepsis, associated with corticosteroid pulses and respiratory physiotherapy improve COVID-19 pneumonia in postoperative lung surgery (23) . Stoleriu and Huang, in their series of 2 and 3 cases respectively, found that mortality may be very high in patients who contract SARS-CoV-2 pneumonia after lung lobectomy and underline that lung surgery should be performed with extreme caution in SARS-CoV-2 epidemic outbreak areas and underline the vigilance required in the perioperative setting (24) (25) . In addition, we recommend consideration of a tailored surgical strategy, especially in patients presenting high risk factors. Despite this, we showed only a correlation between the number of resected segments and COVID-19, parenchymal sparing procedures could be preferred to standard lobectomy, when tumor stage is permissive, even if respiratory and cardiac function are good for larger resections, as long as respecting current recommendations on margins. di 22 As concerning association between duration of surgery and COVID-19 onset, we underline that, regardless of the pandemic, several studies have already reported ventilation-induced lung injury among adverse complications after thoracic surgery (26-27-28) . It is well-known that acute lung injury (ALI) is an acute inflammatory disorder, characterized by disrupted vascular integrity but increased permeability of epithelium and endothelium (29) (30) . Pulmonary damage in the form of acute lung injury and adult respiratory distress syndrome is a major cause of morbidity and mortality after thoracic surgery. Its incidence is about 2-5% of all cases and correlates with duration of surgery (26) . Our data revealed an association between duration of surgery with COVID-19 onset, as well. Based on these results, strategies to reduce surgical time may be considered, such as encouraging preoperative diagnosis, to avoid frozen section or avoid nodal dissection, when possible as in the case of pure GGO. Moreover, since no association emerged between open surgery and VATS, it could be suggested that each surgeon considers the most time saving approach with a view to personal expertise in the field of minimal invasive surgery. Some authors even proposed to delay surgery; however this proposal may be weakened since the end of the pandemic is unknown. It could instead be more feasible using alternative therapies (i.e. SBRT) (31) (32) . Unfortunately, this is a retrospective study, affected by many limitations. The main ones are the small size of the COVID-19 population and incomplete follow-up of patients operated on in March, therefore, we can only draw initial suggestions but further data is definitively needed to strengthen our findings. This bias could be overcome by the use of a web global registry, as TERAVOLT introduced in March 2020 (33) . Another important bias is represented by the testing strategy, which did not included postoperative swab in asymptomatic patients. Moreover, also COVID-19 diagnosis was sometimes obtained only on CT findings without swab confirmation. This meant that, Group 2 may have comprised patients who acquired the infection without developing the disease. That is why, it is worth emphasizing di 22 that, in this study, we always refer to the confirmed disease and not to mere infection. However, that could be a minor bias considering our aim to understand the impact of the disease after surgery rather than the risk of contracting the virus. The final bias is the heterogeneity of the sample determined by multicentric study design. In fact, results could have been influenced by different geographical incidence of the infection but also by the absence of a common protocol in patients management. The outbreak of Coronavirus 2019 is a new challenge in the management of thoracic surgery patients who are exposed to high risk of death if they develop clinically apparent COVID-19. Our results could be potentially useful in patients' triage and postoperative management during the coming months until a vaccine is developed and widely administered. Our suggestions for mitigating risk in surgical patients during the COVID-19 pandemic include: 1. Improve and develop new models for symptoms surveillance and isolation during postoperative and recovery period; Be aware of a possible greater risk correlated with BMI, smoking history, DLCO/VA%, number of resected segments and duration of surgery. Although univariable analysis showed an association between operative duration and development of symptomatic postoperative Covid 19, further data is necessary to define the relationship between a surgical strategy based on parenchymal sparing and minimization of procedure time, and risk to contract the disease (Figure 1 ). di 22 Our data showed that symptomatic COVID-19 severely increases risk of death after surgery. So, we suggest to consider a patient tailored surgical programme based on after discharge surveillance or isolation and to be aware of a possible greater risk correlated with BMI, smoking history, DLCO/VA%, number of resected segments and duration of surgery. di 22 The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) Regione Lombardia, Coronavirus updated epidemiological data Dipartimento della Protezione Civile. Coranavirus, the state of the infection in Italy Mapped out: which European regions have been most severely affected by the coronavirus? Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy et alPatients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak Guidance for management of cancer surgery during the COVID-19 pandemic Thoracic Surgery Outcomes Research Network, Inc. COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement from Thoracic Surgery Outcomes Research Network Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (Released by National Health Commission & State Administration of Traditional Chinese Medicine Covid-19: all non-urgent elective surgery is suspended for at least three months in England Novel Coronavirus Disease (COVID-19) Epidemic Period Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis.The Journal of Thoracic and Cardiovascular Surgery Full spectrum of COVID-19 severity still being depicted Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Coronavirus Disease 2019 in the Perioperative Period of Lung Resection: A Brief Report From a Single Thoracic Surgery Department in Wuhan, People's Republic of China Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: A systematic review and meta-analysis. medRxiv BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank Zheming Liu,et.al Clinical Features and Short-term Outcomes of Elderly Patients With COVID-19 Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia SARS-COV-2 infection in the perioperative of pulmonary lobectomy. About a case Clinical course of patients infected with severe acute respiratory syndrome coronavirus 2 soon after thoracoscopic lung surgery Clinical Course of Three Postoperative Symptomatic COVID-19 Cases in Patients After Lung Lobectomy Lung injury after thoracic surgery and one-lung ventilation Acute lung injury and outcomes after thoracic surgery Acute lung injury in thoracic surgery Endothelial cell signaling and ventilator-induced lung injury: Molecular mechanisms, genomic analyses, and therapeutic targets COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network Thoracic Cancers International COVID-19 Collaboration A special thanks for the collaboration go to Gabrile Maffeis MD 1 , Alessandro Baisi MD 2 , Giovanna Rizzardi MD 3 , Diego Gavello MD 4 , Francesco Carleo MD 7 .